Paper Details

  1. Home
  2. Paper Details

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.

Author: BaertschMarc-Andrea, FenkRoland, GoernerMartin, GoldschmidtHartmut, GraevenUllrich, HaenelMathias, HielscherThomas, HillengaßJens, HoAnthony D, HoseDirk, JauchAnna, KleinStefan, KunzChristina, LindemannHans W, LuntzSteffen, MaiElias K, MartinHans, MerzMaximilian, NogaiAxel, NoppeneyRichard, RaabMarc S, ReimerPeter, SalwenderHans, ScheidChristof, SchlenzkaJana, Schmidt-HieberMartin, Schmidt-WolfIngo G H, WeiselKatja, WuchterPatrick

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Lenalidomide/dexamethasone has become a standard second-line treatment for relapsed multiple myeloma (MM) patients. The ReLApsE trial aims to evaluate the effectiveness of high-dose chemotherapy consolidation plus autologous stem cell transplantation after lenalidomide/dexamethasone induction and maintenance therapy compared to the standard lenalidomide/dexamethasone regimen.
Paper Details　
Original Abstract of the Article :
Despite novel therapeutic agents, most multiple myeloma (MM) patients eventually relapse. Two large phase III trials have shown significantly improved response rates (RR) of lenalidomide/dexamethasone compared with placebo/dexamethasone in relapsed MM (RMM) patients. These results have led to the ap...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845347/

データ提供：米国国立医学図書館（NLM）

ReLApsE Trial: A New Approach to Treating Relapsed Multiple Myeloma

The field of multiple myeloma (MM) research is constantly evolving, seeking new ways to treat this challenging disease. This study outlines the design of the ReLApsE trial, a phase III clinical trial that aims to compare the effectiveness of two treatment regimens for relapsed MM. The researchers seek to determine if adding autologous stem cell transplantation to the standard lenalidomide/dexamethasone treatment can improve outcomes.

A New Treatment Strategy for Relapsed Multiple Myeloma

The ReLApsE trial is a significant step forward in the treatment of relapsed MM. By comparing the efficacy of two different treatment approaches, the trial aims to identify the most effective strategy for improving patient outcomes. This is like searching for the best route through a vast desert – understanding the potential benefits of different pathways can lead to a more successful journey.

Understanding the Role of Autologous Stem Cell Transplantation

The ReLApsE trial explores the potential benefits of autologous stem cell transplantation in combination with lenalidomide/dexamethasone. This approach aims to improve treatment effectiveness and potentially extend survival time. It's like a well-stocked caravan – having the right tools and resources can help us overcome the challenges of a desert trek.

Dr.Camel's Conclusion

The ReLApsE trial is a testament to the ongoing search for better treatments for relapsed MM. It provides us with a promising new avenue to improve patient outcomes and potentially conquer this challenging disease. Like a skilled navigator crossing the desert, researchers are tirelessly searching for new solutions to improve the lives of patients.

Date :
  1. Date Completed 2016-12-13
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

27114074

DOI: Digital Object Identifier

PMC4845347

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.